Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Inivata: Presentation of New Data on Inivata's Industry-Leading Liquid Biopsy Platform at AACR 2018 Annual Meeting

Inivata
Posted on: 11 Apr 18

Presentation of New Data on Inivata's Industry-Leading Liquid Biopsy Platform at AACR 2018 Annual Meeting


Oral presentations and posters to feature Inivata's InVision® liquid biopsy platform
and its application

Research Triangle Park, NC and Cambridge, UK, April 11, 2018 -- Inivata , a global clinical cancer genomics company utilizing an industry-leading liquid biopsy platform to transform patient care, announces that cutting-edge data on the performance of its liquid biopsy platform, InVision®, will be showcased in two oral presentations and two posters at the American Association for Cancer Research (AACR) Annual Meeting 14-18 April in Chicago. The details are as follows:

Presentation: Longitudinal circulating-tumor DNA profiling of EGFR-mutated non-small cell lung cancer patients treated with EGFR-tyrosine kinase inhibitors
Date and time: April 15, 2018, 3:20PM - 3:35PM
Location: Room S105 - McCormick Place South (Level 1)
For the list of authors, click here . Webcast Available May 9

Presentation: Analytical validation of InVisionFirst(TM), a liquid biopsy assay for high-sensitivity broad molecular profiling of circulating tumor DNA using plasma samples of cancer patients
Date and time: April 15, 2018, 3:50PM - 4:05PM
Location: Room S105 - McCormick Place South (Level 1)
For the list of authors, click here . Webcast Available May 9

Poster: Integrative analysis of resistance to BRAF-targeted therapies in lung adenocarcinomas
Date and time: April 16, 2018, 8:00AM - 12:00PM
Location: Section 36
For the list of authors, click here .

Poster: Feasibility of an amplicon-based liquid biopsy for ALK and ROS1 fusions in advanced non-small cell lung cancer (NSCLC) patients
Date and time: April 17, 2018, 1:00 PM - 5:00 PM
Location: Section 27
For the list of authors, click here .

About Inivata
Inivata is a global clinical cancer genomics company utilizing a proprietary, industry-leading liquid biopsy platform to transform patient care.  Using a simple blood test (liquid biopsy), the analysis of ctDNA is a new lower-cost, less invasive, highly sensitive method for oncologists to diagnose and monitor cancer progression and treatment. The InVision® liquid biopsy platform is based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge, combines industry-leading sensitivity with select multi-gene panels to provide clinically actionable information to clinicians. Inivata has established collaborations with world-leading cancer centers and academic institutions, and is partnering with pharmaceutical and biotechnology companies.  The Company has a CLIA lab in Research Triangle Park, NC and laboratories in Cambridge, UK. For more information, please go to www.inivata.com . Follow us on Twitter @Inivata.

Media Contacts:
Consilium Strategic Communications
Chris Gardner/Laura Thornton
inivata@consilium-comms.com +44 (0)20 3709 5700

Karen Chandler-Smith
karen.chandler-smith@inivata.com +44 (0)7900 430235



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Inivata via GlobeNewswire
HUG#2183250
GlobeNewswire
globenewswire.com

Last updated on: 12/04/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.